Key statistics
On Friday, Recursion Pharmaceuticals Inc (RXRX:NSQ) closed at 7.10, 41.01% above the 52 week low of 5.04 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.86 |
---|---|
High | 7.21 |
Low | 6.81 |
Bid | 7.14 |
Offer | 7.20 |
Previous close | 6.93 |
Average volume | 4.76m |
---|---|
Shares outstanding | 286.64m |
Free float | 266.99m |
P/E (TTM) | -- |
Market cap | 2.04bn USD |
EPS (TTM) | -1.53 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
- Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
- Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
- Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
- Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
- Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
- CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
- Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
- Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
- Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
- Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
More ▼